Related Experiment Video
Updated: Feb 22, 2026

06:00
Author Spotlight: Development of a Smartphone-Enhanced Paper-Based Device for Rapid Dengue NS1 Detection
Published on: January 26, 2024
2.1K
Colorimetric detection of D-dimer in a paper-based immunodetection device
Sónia Ruivo1, Ana M Azevedo1, Duarte M F Prazeres1
1iBB- Institute for Bioengineering and Biosciences, Department of Bioengineering, Instituto Superior Técnico, Universidade de Lisboa, Av. Rovisco Pais, 1049-001 Lisboa, Portugal.
Analytical Biochemistry
|September 20, 2017
Summary
A novel microfluidic paper-based analytical device (μPAD) immunoassay effectively detects the D-dimer biomarker in blood. This low-cost diagnostic tool shows promise for rapid and accessible clinical testing.
Area of Science:
- Biomedical Engineering
- Analytical Chemistry
- Immunodiagnostics
Background:
- D-dimer is a critical blood biomarker for diagnosing thrombotic events.
- Current diagnostic methods can be time-consuming and expensive.
- There is a need for rapid, point-of-care diagnostic tools for D-dimer detection.
Purpose of the Study:
- To develop and validate a microfluidic paper-based analytical device (μPAD) for D-dimer detection.
- To assess the sensitivity and linearity of the μPAD immunoassay.
- To evaluate the potential clinical utility of the μPAD for D-dimer screening.
Main Methods:
- Fabrication of μPADs using wax printing on chromatographic paper.
- Immobilization of anti-D-dimer capture antibodies.
- Conjugation of anti-D-dimer antibodies with 40 nm gold nanoparticles for signal amplification.
- Testing of buffer and simulated plasma samples with varying D-dimer concentrations.
Main Results:
- Successful detection of D-dimer in samples down to 15 ng/mL.
- Observed linear correlation between signal intensity and D-dimer concentration up to 100 ng/mL.
- Demonstrated potential for clinical relevance by achieving positive results above 250-500 ng/mL with appropriate dilution.
Conclusions:
- μPADs offer a promising platform for sensitive and specific D-dimer detection.
- The developed immunoassay demonstrates potential for cost-effective, point-of-care diagnostics.
- Further comparison with lateral flow devices is warranted to fully understand the merits and pitfalls.

